Physician profile
Robert Engle
NPI 1437449907
$5,696.17
in general payments reported to CMS, 2019-2025
33 companies · $717 in 2025
The $717 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $377 · 2021: $845 · 2022: $735 · 2023: $734 · 2024: $879 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,324.60 | 2019-2025 | Xpress Loprofile, Na, Colorado |
| Glaxosmithkline, LLC. | $603.73 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $445.44 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $374.21 | 2019-2025 | Xywav |
| Csl Behring | $362.04 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $294.35 | 2020-2025 | Cuvitru, Hyqvia |
| Aerin Medical INC. | $283.16 | 2023-2025 | |
| Genzyme Corporation | $276.27 | 2021-2025 | |
| Harmony Biosciences LLC | $218.30 | 2020-2024 | Wakix |
| Optinose US, INC. | $201.51 | 2019-2024 | |
| Grifols USA, LLC | $178.57 | 2020-2024 | Xembify |
| Astrazeneca Pharmaceuticals LP | $137.88 | 2019-2020 | |
| Neurent Medical Limited | $98.91 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Amgen INC. | $84.14 | 2025 | Tezspire |
| Pharming Healthcare, INC. | $77.78 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $77.12 | 2019-2021 | |
| Kaleo, INC. | $73.70 | 2019-2023 | Auvi-Q |
| Medtronic, INC. | $70.18 | 2022-2024 | Propel |
| Intersect Ent, INC. | $66.98 | 2021-2022 | |
| Pfizer INC. | $54.33 | 2019 | |
| Alk-Abello, INC | $54.30 | 2019-2021 | |
| Smith+Nephew, INC. | $44.47 | 2019 | |
| Merck Sharp & Dohme LLC | $42.85 | 2021-2023 | |
| Greer Laboratories, INC. | $39.06 | 2019 | |
| Ethicon US, LLC | $35.37 | 2019 | |
| Axsome Therapeutics, INC. | $31.84 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $29.75 | 2024 | Lumryz |
| Shire North American Group INC | $29.21 | 2019 | |
| Acclarent, INC | $25.34 | 2019 | |
| Aimmune Therapeutics, INC. | $20.49 | 2021 | |
| Karl Storz Endoscopy-America | $15.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.01 | 2021 | |
| Genentech USA, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.